BBIO BridgeBio Pharma Inc

Price (delayed)

$55.65

Market cap

$8.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.8

Enterprise value

$8.43B

Sector: Healthcare
Industry: Biotechnology

Highlights

BridgeBio Pharma's gross margin has increased by 7% YoY
BBIO's equity has dropped by 86% year-on-year and by 65% since the previous quarter
BridgeBio Pharma's revenue has plunged by 80% YoY and by 62% from the previous quarter

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
148.96M
Market cap
$8.29B
Enterprise value
$8.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
117.79
Price to sales (P/S)
796.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,021.84
Earnings
Revenue
$8.25M
EBIT
-$412.07M
EBITDA
-$408.98M
Free cash flow
-$407.09M
Per share
EPS
-$3.8
Free cash flow per share
-$3.45
Book value per share
$0.47
Revenue per share
$0.07
TBVPS
$5.96
Balance sheet
Total assets
$703.59M
Total liabilities
$595.7M
Debt
$495.79M
Equity
$57.91M
Working capital
$547.18M
Liquidity
Debt to equity
8.56
Current ratio
6.72
Quick ratio
6.35
Net debt/EBITDA
-0.34
Margins
EBITDA margin
-4,957.9%
Gross margin
100%
Net margin
-5,439.7%
Operating margin
-5,752%
Efficiency
Return on assets
-53%
Return on equity
-206.8%
Return on invested capital
-55.5%
Return on capital employed
-67.8%
Return on sales
-4,995.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-0.45%
1 week
0.96%
1 month
-15.41%
1 year
87.37%
YTD
-21.74%
QTD
-9.66%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$8.25M
Gross profit
$8.25M
Operating income
-$474.48M
Net income
-$448.72M
Gross margin
100%
Net margin
-5,439.7%
BBIO's net margin has dropped by 197% since the previous quarter
BBIO's operating margin has shrunk by 197% QoQ
BridgeBio Pharma's revenue has plunged by 80% YoY and by 62% from the previous quarter
The gross profit has plunged by 78% YoY and by 62% from the previous quarter

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
117.79
P/S
796.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,021.84
BBIO's EPS has dropped by 53% year-on-year and by 11% since the previous quarter
The P/B is 133% above the last 4 quarters average of 50.7
BBIO's equity has dropped by 86% year-on-year and by 65% since the previous quarter
The stock's price to sales (P/S) is 129% more than its last 4 quarters average of 349.4
BridgeBio Pharma's revenue has plunged by 80% YoY and by 62% from the previous quarter

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS has dropped by 194% since the previous quarter
The ROIC has soared by 63% YoY and by 6% from the previous quarter
The return on equity has dropped by 57% since the previous quarter but it has increased by 39% year-on-year
The ROA has contracted by 9% from the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 18% greater than its total liabilities
BridgeBio Pharma's quick ratio has decreased by 33% from the previous quarter and by 30% YoY
The current ratio has decreased by 32% QoQ and by 29% YoY
BBIO's debt to equity has surged by 190% since the previous quarter
BBIO's equity has dropped by 86% year-on-year and by 65% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.